This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
ThousandOaks-based seed biotechnology developer Ceres reports this morning that it has been awarded a U.S. patent on a genetic sequence derived from corn. The company said the patent, U.S. PTO, the inventors of the patent were Nicholai Alexandrov, Vyacheslav Brover, and Kenneth Feldman. According to the U.S.
ThousandOaks-based Amgen said Friday afternoon that it has resolved a patent litigation suite with Teva. and Teva Pharmaceuticals USA, prohibiting them from infringing on its patents for human g-CSF.
ThousandOaks-based agricultural biotechnology develper Ceres announced this morning that it has received a U.S. patent, covering the company's genetic sequence derived from soybean, which is aimed at producing improved soybean varieties. The new patent, U.S. The new patent, U.S. in the patent filing.
ThousandOaks-based Amgen has scored a win in court, after a jury upheld two patents held by the company for its drug Repatha, which is used to treat ultra-high LDL cholesterol. Amgen had been sued by Sanofi and Regeneron Pharmaceuticals over patent infringement.
ThousandOaks-based Dyve Biosciences , a biotech company developing drug delivery technology, has named Chuck Harbert, Ph.D. Dyve said that Dr. Harbert is author or co-author of approximately twenty scientific publications and inventor or co-inventor of approximately thirty-five pharmaceutical patents, including ZOLOFT.
ThousandOaks-based Amgen and AbbVie have settled a series of lawsuits against each other, saying this morning that they have agreed to resolve all pending litigation regarding AMGEVITA/AMJEVITA, a biosimilar which is based on AbbVie's Humira (adalimumab).
ThousandOaks-based agricultural biotechnology developer Ceres reports that it hs received two, U.S. patents on crop traits that it says it is looking to apply to such crops as corn, soybean, forage sorghum and cotton. The two patents are U.S. 9,309,573, and bring the company's total number of patents to approximately 90.
Mann had long sold the company and patents, but one of their providers which had been installing them surgically, and had started installing parts from China. The concept of the incubator is we''re raising a fund here locally and ten percent is local the other 90 percent on AngelList, and we''ll be locating here in the town of ThousandOaks.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content